Apnimed: Buy Rating Reiterated on Strong Oxnimbi OSA Profile and Unchanged $50 Price Target
at www.tipranks.com (Wed, 9-Sep 9:15 AM)
Apnimed, Inc. reports Q2 results
at seekingalpha.com (Tue, 8-Sep 4:41 PM)
